Aimee C Hodowanec1,2, Rebecca D Lee3, Kirsten E Brady4, Weihua Gao5, Stacey Kincaid6, Jill Plants7, Mieoak Bahk8, Nigel Mackman9, Alan L Landay10, Gregory D Huhn11,12. 1. Ruth M. Rothstein CORE Center, 2020 W. Harrison St, Chicago, IL, 60612, USA. aimee_hodowanec@rush.edu. 2. Rush University Medical Center, Section of Infectious Diseases, Chicago, IL, USA. aimee_hodowanec@rush.edu. 3. University of North Carolina at Chapel Hill, Division of Hematology and Oncology, Chapel Hill, NC, USA. rlee@wakehealth.edu. 4. Rush University Medical Center, Department of Immunology and Microbiology, Chicago, IL, USA. kirsten_brady@rush.edu. 5. Center for Clinical and Translational Sciences, University of Illinois at Chicago, Chicago, IL, USA. weihua.gao2@gmail.com. 6. Ruth M. Rothstein CORE Center, 2020 W. Harrison St, Chicago, IL, 60612, USA. slk1220@aol.com. 7. Rush University Medical Center, Department of Immunology and Microbiology, Chicago, IL, USA. jill_plants@rush.edu. 8. Ruth M. Rothstein CORE Center, 2020 W. Harrison St, Chicago, IL, 60612, USA. mbahk@cookcountyhhs.org. 9. University of North Carolina at Chapel Hill, Division of Hematology and Oncology, Chapel Hill, NC, USA. nigel_mackman@med.unc.edu. 10. Rush University Medical Center, Department of Immunology and Microbiology, Chicago, IL, USA. alan_landay@rush.edu. 11. Ruth M. Rothstein CORE Center, 2020 W. Harrison St, Chicago, IL, 60612, USA. gregory_huhn@rush.edu. 12. Rush University Medical Center, Section of Infectious Diseases, Chicago, IL, USA. gregory_huhn@rush.edu.
Abstract
BACKGROUND: Tissue factor (TF) is a protein that mediates the initiation of the coagulation cascade. TF expression is increased in patients with poorly-controlled HIV, and may be associated with increased immune activation that leads to cardiovascular morbidity. The role of TF in immune activation in liver disease in hepatitis C virus (HCV)-monoinfection and HIV/HCV-coinfection has not been explored. METHODS: Fifty-nine patients were stratified: A) HIV-monoinfection (N = 15), B) HCV-monoinfection with chronic hepatitis C (CHC) (N = 15), C) HIV/HCV-coinfection with CHC (N = 14), and D) HIV/HCV-seropositive with cleared-HCV (N = 15). All HIV+ patients had undetectable HIV viremia. Whole blood was collected for CD4/CD8 immune activation markers by flow cytometry and plasma was assayed for microparticle TF (MPTF) activity. Subjects underwent transient elastography (TE) to stage liver fibrosis. Undetectable versus detectable MPTF was compared across strata using Fisher's Exact test. RESULTS: MPTF activity was more frequently detected among patients with HCV-monoinfection (40%), compared to HIV-monoinfection and HIV/HCV-seropositive with cleared HCV (7%) and HIV/HCV-coinfection with CHC (14%) (p = 0.02). Mean TE-derived liver stiffness score in kPa was higher in patients with detectable MPTF (12.4 ± 8.5) than those with undetectable MPTF (6.4 ± 3.0) (p = 0.01). Mean CD4 + HLADR+ and CD4 + CD38-HLADR+ expression were higher in those with detectable MPTF (44 ± 9.8% and 38 ± 8.7%, respectively) than those with undetectable MPTF (36 ± 11% and 31 ± 10.4% respectively) (p = 0.05 and 0.04 respectively). CONCLUSIONS: HCV-monoinfection and HIV/HCV-coinfection with CHC were associated with MPTF activity. MPTF activity is also associated with advanced liver fibrosis and with CD4 + HLADR+ immune activation.
BACKGROUND:Tissue factor (TF) is a protein that mediates the initiation of the coagulation cascade. TF expression is increased in patients with poorly-controlled HIV, and may be associated with increased immune activation that leads to cardiovascular morbidity. The role of TF in immune activation in liver disease in hepatitis C virus (HCV)-monoinfection and HIV/HCV-coinfection has not been explored. METHODS: Fifty-nine patients were stratified: A) HIV-monoinfection (N = 15), B) HCV-monoinfection with chronic hepatitis C (CHC) (N = 15), C) HIV/HCV-coinfection with CHC (N = 14), and D) HIV/HCV-seropositive with cleared-HCV (N = 15). All HIV+ patients had undetectable HIV viremia. Whole blood was collected for CD4/CD8 immune activation markers by flow cytometry and plasma was assayed for microparticle TF (MPTF) activity. Subjects underwent transient elastography (TE) to stage liver fibrosis. Undetectable versus detectable MPTF was compared across strata using Fisher's Exact test. RESULTS:MPTF activity was more frequently detected among patients with HCV-monoinfection (40%), compared to HIV-monoinfection and HIV/HCV-seropositive with cleared HCV (7%) and HIV/HCV-coinfection with CHC (14%) (p = 0.02). Mean TE-derived liver stiffness score in kPa was higher in patients with detectable MPTF (12.4 ± 8.5) than those with undetectable MPTF (6.4 ± 3.0) (p = 0.01). Mean CD4 + HLADR+ and CD4 + CD38-HLADR+ expression were higher in those with detectable MPTF (44 ± 9.8% and 38 ± 8.7%, respectively) than those with undetectable MPTF (36 ± 11% and 31 ± 10.4% respectively) (p = 0.05 and 0.04 respectively). CONCLUSIONS:HCV-monoinfection and HIV/HCV-coinfection with CHC were associated with MPTF activity. MPTF activity is also associated with advanced liver fibrosis and with CD4 + HLADR+ immune activation.
Authors: B Soto; A Sánchez-Quijano; L Rodrigo; J A del Olmo; M García-Bengoechea; J Hernández-Quero; C Rey; M A Abad; M Rodríguez; M Sales Gilabert; F González; P Mirón; A Caruz; F Relimpio; R Torronteras; M Leal; E Lissen Journal: J Hepatol Date: 1997-01 Impact factor: 25.083
Authors: Marta Catalfamo; Christopher Wilhelm; Lueng Tcheung; Michael Proschan; Travis Friesen; Jung-Hyun Park; Joseph Adelsberger; Michael Baseler; Frank Maldarelli; Richard Davey; Gregg Roby; Catherine Rehm; Clifford Lane Journal: J Immunol Date: 2011-01-21 Impact factor: 5.422
Authors: Gregory D Kirk; Jacquie Astemborski; Shruti H Mehta; Chuck Spoler; Cedric Fisher; Danisha Allen; Yvonne Higgins; Richard D Moore; Nezem Afdhal; Michael Torbenson; Mark Sulkowski; David L Thomas Journal: Clin Infect Dis Date: 2009-04-01 Impact factor: 9.079
Authors: Maria Boddi; Rosanna Abbate; Benedetta Chellini; Betti Giusti; Carlo Giannini; Giovanni Pratesi; Luciana Rossi; Carlo Pratesi; Gian Franco Gensini; Laura Paperetti; Anna Linda Zignego Journal: J Clin Virol Date: 2009-11-05 Impact factor: 3.168
Authors: Adeel A Butt; Wang Xiaoqiang; Matthew Budoff; David Leaf; Lewis H Kuller; Amy C Justice Journal: Clin Infect Dis Date: 2009-07-15 Impact factor: 9.079
Authors: Juan Lin; Xiaonan Xue; Kathryn Anastos; Mardge H Cohen; Stephen J Gange; Jason M Lazar; Chenglong Liu; Wendy J Mack; Phyllis C Tien; Cathy Tilley; Howard N Hodis; Alan L Landay; Russell P Tracy; Robert C Kaplan; David B Hanna Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.771
Authors: Clare M Schmedes; Steven P Grover; Yohei M Hisada; Marco Goeijenbier; Johan Hultdin; Sofie Nilsson; Therese Thunberg; Clas Ahlm; Nigel Mackman; Anne-Marie Fors Connolly Journal: J Infect Dis Date: 2020-09-14 Impact factor: 5.226
Authors: Caian L Vinhaes; Mariana Araujo-Pereira; Rafael Tibúrcio; Juan M Cubillos-Angulo; Fernanda O Demitto; Kevan M Akrami; Bruno B Andrade Journal: Life (Basel) Date: 2021-01-18